

Vor ref 22259 XX 1

PATENTFAMILIE DE 30 22 337

20. november 1998

1

File 351:DERWENT WPI 1963-1998/UD=9846;UP=9843;UM=9841
(c)1998 Derwent Info Ltd

1/7/1

DIALOG(R)File 351:DERWENT WPI

(c)1998 Derwent Info Ltd. All rts. reserv.

003444375

WPI Acc No: 82-01972E/*198202*

Compsns. for contraception or treatment of gynaecological disorders -
contg. 6 beta, 7 beta; 15 delta, 16

beta-dimethylene-3-oxo-4-androstene-17(beta-1')-spiro-5'-perhydrofuran-2'-one

Patent Assignee: SCHERING AG (SCHD)

Inventor: BEIER S; ELMER W; MANNESMANN G; SCHILLINGE E

Number of Countries: 001 Number of Patents: 004

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Main IPC	Week
DE 3022337 A	19820107	DE 3051166 A	19800611				198202 B
DE 3051166 A	19890323	DE 3022337 A	19800611				198913
DE 3022337 C	19891019					198942	
DE 3051166 C	19901018					199042	

Priority Applications (No Type Date): DE 3022337 A 19800611; DE 3051166 A 19800611

Patent Details:

Patent Kind Lan Pg Filing Notes Application Patent

DE 3022337 A 9

Abstract (Basic): DE 3022337 A

New preps. for contraception and for the treatment of gynaecological disorders are based on 6 beta, 7 beta; 15 beta, 16 beta-dimethylene-3-oxo-4-androstene/17 (beta-1')-spiro-5'-perhydrofuran-2'-one (I).

(I) (a known aldosterone-antagonist diuretic) has been found to display marked gestagenic activity, as shown by its positive effects in a modified Clauberg test in rabbits at dosages of 0.1-1.0 mg s.c. It may be used alone or in combination with an oestrogen as a contraceptive agent, esp. in women suffering from high blood pressure or in whom oral contraceptives cause hypertension. (I) may also be used for the treatment of premenstrual disorders. It is similar to progesterone in its combination of gestagenic and anti-mineralocorticoid properties, with the advantage of oral activity.

Derwent Class: B01

International Patent Class (Additional): A61K-031/56